Gastroesophageal Reflux Disease Therapeutics Market
Report ID: SQMIG35I2721
Report ID: SQMIG35I2721
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2721 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
174
|Figures:
79
Global Gastroesophageal Reflux Disease Therapeutics Market size was valued at USD 6.70 Billion in 2024 and is poised to grow from USD 6.95 Billion in 2025 to USD 9.37 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).
The gastroesophageal reflux disease therapeutics market growth is driven by increasing rates of GERD around the world as well as greater access to diagnosing it, which generates ongoing demand for therapies to treat either chronically or acutely. This market consists of therapies that include prescription medications that suppress acid secretion, non-prescription medications that relieve GERD symptoms, surgical and endoscopy treatment options, as well as diagnostic tools, of which all add to the overall cost of treating GERD and therefore add to the economic burden of GERD, yet there has been a shift away from aggressive surgical treatment to the ubiquitous use of proton pump inhibitors (PPIs), as evidenced by the marketplace for PPIs dominated by omeprazole.
The gastroesophageal reflux disease therapeutics market trends for PPIs has expanded beyond PPIs alone through the introduction of a broader offering of potassium competitive acid blockers, minimally invasive surgical options, and improved global diagnostic tools for locating GERD early and accurately. As such, one of the primary forces that is influencing the market for Gastroesophageal RefluxThe development of PPI resistant (patients who do very poorly on PPI therapy and have atypical reflux patterns aka non-acidic reflux), physicians have turned toward potassium competitive acid blockers, less invasive surgical options via endoscopic fundoplication, and/or neuromodulatory devices; thus, resulting higher procedure volume at tertiary referral centers and increased interest from manufacturers to provide appropriate, companion diagnostic tools. These factors lead to increasing R&D expenditures as well as new opportunities to remediate the historical lack of access for GERD diagnosis or treatment, which will only increase as the number of people with GERD increases. For Example; Individuals Diagnosed with Severe PPI Resistant GERD will see
How is AI Improving Drug Discovery and Personalization in the Gastroesophageal Reflux Disease Therapeutics Market?
AI technology is significantly impacting how drugs are developed and personalized for use within the GERD therapeutic area, by accelerating target identification, creating superior molecules, as well as identifying patient-specific phenotypes. AI facilitates virtual drug screening and can also provide estimates of candidate pharmacokinetic properties as part of drug discovery activities; in the context of personalizing medicine, AI enables patient stratification derived from clinical history, behaviour and symptoms which can subsequently aid in identifying the correct biomarker for incorporation into the clinical study/trial; With the recently introduced new acid-suppressing therapies and the advances made within the device-based therapy arena, AI can further aid in “derisking” the development of therapies through improved clinical study and trial design for clinically relevant subgroups. As a result of these changes to the drug and therapy development processes, clinical development of novel therapies will be more efficient and improve the probability that these therapies will be delivered to the appropriate patients.
In December 2022, Phathom reported positive phase 3 trial results for Vonoprazan (an acid-suppressor), demonstrating a statistically significant reduction in heartburn at night and the continuation of strong clinical momentum through collaboration with AI enabled analytics to decrease patient timeline of involvement in clinical trials and to accelerate trial timelines while derisking development and allowing payers/providers to effectively match novel therapies with patients.
Market snapshot - (2026-2033)
Global Market Size
USD 6.7 Billion
Largest Segment
Proton Pump Inhibitors (PPIs)
Fastest Growth
Potassium-Competitive Acid Blockers (P-CABs)
Growth Rate
3.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global gastroesophageal reflux disease therapeutics market is segmented by drug class, disease type, route of administration, distribution channel, end user, patient group and region. Based on drug class, the market is segmented into proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, prokinetic agents, potassium-competitive acid blockers (P-CABs) and others. Based on disease type, the market is segmented into erosive GERD, non-erosive reflux disease (NERD), refractory GERD and GERD with Barrett’s esophagus. Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics and homecare settings. Based on patient group, the market is segmented into pediatric, adult and geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The proton pump inhibitors are the most common choice for acid suppression and for healing the mucosal surfaces of the esophagus; they are the foundation of all treatment options for GERD. They have a solid reputation among clinicians and have a long history of safety, and their strong place in clinical practice guidelines contributes to the large number of prescriptions written for PPIs. Their consistent level of therapeutic effectiveness supports their place on formulary lists and their reimbursement under insurance agreements for clinicians; therefore, there is continued opportunity for the development and use of more effective formulations.
However, the potassium-competitive acid blockers are the fastest-growing drug class to treat GERD. They have a unique way of working that provides rapid and sustained acid control, are becoming more familiar to clinicians, and regulatory approval for these products is gaining momentum. The growing number of clinicians who will have been exposed to these products, combined with the active development of many clinical guidelines, means that many new indications will soon become available, creating a large number of high-value opportunities for differentiated formulations and for new uses.
The NERD segment represents the largest percentage of patients diagnosed with symptomatic GERD who are treated primarily with pharmaceuticals; thus, there is ongoing demand for medications. Diagnosing GERD symptoms, managing GERD patients in primary care settings, and the continuing effects on quality of life are all factors that are leading to long-term treatment approaches. This ongoing focus on the clinical element of diagnosing GERD has led to continued research on product development, product formulation options, and personalized therapeutic approaches to NERD, which are all key components in the activity and planning of commercial activities within the marketplace.
In contrast, refractory GERD is experiencing the highest growth due to the unmet need for new pharmacological and interventional therapies. Increased research activity to actively develop novel medical devices to treat GERD and interest in developing targeted therapies for patients failing conventional treatment has expanded referral sources and maximized commercial/clinical opportunities within the therapeutic area for reflux disease.
To get detailed segments analysis, Request a Free Sample Report
The dominance of North America in the reflux therapeutics market is due to its highly developed clinical research infrastructure, concentration of manufacturer operations, and the ability to develop and distribute new products through one of the most integrated health care delivery systems in the world. A large network of specialty centers and academic institutions will enable rapid clinical evaluations and provide real-world evidence for new drugs, while formalized engagement pathways with regulators and payers will allow for timely access to market for new products. The high level of clinical awareness among physicians, the availability of organized referral mechanisms, and the provision of patient support programs for long-term management are key elements that will support broader adoption of therapies. Collaborative ecosystems between manufacturers, health systems, and research institutions drive innovation and access to market, consolidating North America's position as a leader in the reflux therapeutics market.
Gastroesophageal reflux disease therapeutics market outlook in United States is characterized by a high concentration of research institutions, specialist clinicians and industry headquarters that drive rapid product innovation and clinical adoption. Patient awareness programs and comprehensive specialty care pathways support diagnosis and long term management, while close collaboration between manufacturers and healthcare providers enhances real world evidence generation and formulary placement, sustaining leadership in therapeutic development and clinical application practice integration.
Gastroesophageal reflux disease therapeutics market share in Canada is enhanced by the country’s public health system, which promotes access to specialists and diagnostic services through a well-structured referral network. Through evidence based guidelines, initiatives supporting patient education, and collaborative research programs, there is a coordinated approach to the adoption of new or innovative therapies. Partnerships between academic centres and industry create opportunities for clinical studies and knowledge transfer that will lead to ongoing improvements in the treatment pathways and patient management across multiple care delivery settings.
Rapid expansion in Europe is driven by concentrated clinical expertise, collaborative research networks and evolving care pathways that support earlier diagnosis and broader therapy adoption. Harmonized regulatory engagement and active payer dialogue in key markets help align access strategies, while multicenter clinical initiatives and centers of excellence enhance evidence generation and guideline integration. Manufacturers are tailoring localization efforts, clinical programs and education campaigns to varied national systems, improving clinician awareness and referral practices. Strengthened primary care diagnostic capacity and cross border collaboration further enable optimized treatment sequencing and patient management, positioning Europe as an increasingly dynamic region for reflux therapeutics development.
Gastroesophageal reflux disease therapeutics market penetration in Germany has strong clinical trials and well-established networks with specialists, both of which speed up the usage of different treatments available for GERD. Evidence is produced through strong teamwork between hospitals, hospitals, and the pharmaceutical industry, and evidence is used for health technology assessments. Integrated care pathways, as well as centres of gastroenterological excellence, provide an improvement in referral patterns and provide an opportunity for optimizing treatment through multiple options available; thus, Germany is the leading country in Europe for GERD therapeutics.
Gastroesophageal reflux disease therapeutics market forecast in United Kingdom is expanding rapidly due to proactive guideline evolution, growing specialist networks and targeted awareness programs. Emphasis on primary care diagnostic pathways and efficient referral supports earlier intervention. Collaborative real world evidence initiatives and partnerships between clinical leaders and industry accelerate evaluation and adoption of new therapies, positioning United Kingdom among the fastest growing markets in the European reflux therapeutics landscape and reach.
Gastroesophageal reflux disease therapeutics market analysis in France, clinical collaboration and increased investment in diagnostic capacity are the driving forces behind the development of therapeutic options for patients. New approaches to treating GERD, including improved use of multidisciplinary approaches and referral to regional care centres, are facilitated by the joint use of clinical trials and engagement with both payers and clinicians in building the evidence needed to provide wider access to novel therapies. Continued focus on educating patients about their condition, aligning with practice guidelines related to GERD, and developing integrated care pathways will further contribute to developing the market for GERD therapeutics across all areas of clinical practice.
Asia Pacific is strengthening position through coordinated investments in clinical capacity, local evidence generation and strategic industry partnerships that reflect diverse healthcare models. Regional centers are enhancing diagnostic infrastructure and specialist training while manufacturers pursue localization and collaborative research to support regulatory and payer engagement. Growing emphasis on evidence based practice and adapted treatment pathways supports wider adoption, and cross border initiatives facilitate knowledge exchange and clinical capability building. Investment in digital health tools and patient support programs improves adherence and management, enabling scalable care models that elevate Asia Pacific role in reflux therapeutics across varied systems.
Gastroesophageal reflux disease therapeutics market regional outlook in Japan are growing with sufficient clinical research and clinical engagement to develop solid scientific evidence. The combination of technology diagnostics and specialist gastroenterology centers will assist in determining appropriate patients and optimizing treatment. Collaboration between academic institutions and industry aids in the localization of clinical programs, while patient education and care pathways provide continuity of care in the management of GERD. Together these elements provide Japan with a considerable place in regional development of therapeutics and clinical adoption of therapeutics worldwide.
Gastroesophageal reflux disease therapeutics market regional forecast in South Korea is strengthening through investments in specialist training, diagnostic infrastructure and localized clinical research. Ties between academic centers and industry support initiation of investigatorled studies and knowledge exchange. Emphasis on integrated care models and digital health solutions enhances patient monitoring and adherence, while education campaigns increase awareness among clinicians and patients. These elements contribute to South Korea prominence in regional reflux therapeutics advancement.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence Of GERD
Advances In Pharmacologic Options
High Cost Of Innovative Therapies
Regulatory and Reimbursement Challenges
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape is characterized by strong incumbents and targeted entrants competing through product innovation, device M&A, and diagnostics partnerships. Examples include Phathom’s Voquezna launch that introduced a novel PCAB therapy and Ethicon’s acquisition of Torax Medical for the LINX device, illustrating consolidation in device plays. Diagnostic telemedicine programs and capsule sampling innovations are shifting referral patterns and physician adoption.
Top Player’s Company Profile
Recent Developments in the Gastroesophageal Reflux Disease Therapeutics Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global GERD therapeutics market is being propelled primarily by the rising prevalence of GERD worldwide and expanding diagnostic capacity, while advances in pharmacologic options such as novel acid suppressants and AI-enabled discovery act as a second important driver enhancing targeted therapies and trial efficiency. The market faces a significant restraint from the high cost of innovative therapies that can limit access and payer uptake. North America remains the dominating region due to strong clinical research infrastructure and integrated care pathways, and the Proton Pump Inhibitors segment continues as the dominating drug class because of established efficacy, guideline endorsement and entrenched prescribing patterns.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 6.7 Billion |
| Market size value in 2033 | USD 9.37 Billion |
| Growth Rate | 3.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Gastroesophageal Reflux Disease Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Gastroesophageal Reflux Disease Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Gastroesophageal Reflux Disease Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Gastroesophageal Reflux Disease Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Gastroesophageal Reflux Disease Therapeutics Market size was valued at USD 6.7 Billion in 2024 and is poised to grow from USD 6.95 Billion in 2025 to USD 9.37 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).
Competitive landscape is characterized by strong incumbents and targeted entrants competing through product innovation, device M&A, and diagnostics partnerships. Examples include Phathom’s Voquezna launch that introduced a novel PCAB therapy and Ethicon’s acquisition of Torax Medical for the LINX device, illustrating consolidation in device plays. Diagnostic telemedicine programs and capsule sampling innovations are shifting referral patterns and physician adoption. 'Pfizer', 'Takeda Pharmaceutical Company', 'Phathom Pharmaceuticals', 'Eisai', 'AstraZeneca', 'GSK', 'Johnson & Johnson', 'Bausch Health Companies', 'Teva Pharmaceutical Industries', 'Dr. Reddy's Laboratories', 'Sun Pharmaceutical Industries', 'Cipla', 'Torrent Pharmaceuticals', 'Cadila Pharmaceuticals', 'Sandoz', 'Viatris', 'Daewoong Pharmaceutical', 'Yuhan Corporation', 'Sebela Pharmaceuticals', 'Bayer'
The increasing prevalence of gastroesophageal reflux disease across diverse populations has expanded the pool of patients seeking symptom relief and long term management, prompting greater demand for proven therapeutics. Growth in diagnosed cases encourages physicians and healthcare systems to prioritize treatment pathways, supports expanded prescription volumes, and stimulates pharmaceutical companies to invest in new formulations and delivery technologies. Greater patient awareness and continuing symptom burden drive sustained therapy adherence, which together reinforce market expansion through broader product uptake and deeper penetration into primary care settings.
Personalized Treatment Approaches: Clinicians and developers are shifting toward individualized GERD management that considers patient phenotype, symptom patterns, comorbidities and treatment response to optimize outcomes. Emphasis on biomarker-informed therapy selection, subtype-specific pharmacologic agents, and tailored procedural choices aims to reduce unnecessary exposure and improve quality of life. This trend supports adaptive clinical pathways, enhances shared decision making, fosters targeted drug development, and encourages integrated care models that combine medical, behavioral and lifestyle interventions to address heterogeneity in disease presentation driving measurable patient benefit.
Why does North America Dominate the Global Gastroesophageal Reflux Disease Therapeutics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
